DS
PCRX icon

David Shaw’s Pacira BioSciences PCRX Stock Holding History

David Shaw’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-35,700
Closed -$3.17M – 3904
2014
Q4 		$3.17M Sell
35,700
-23,000
-39% -$2.18M ﹤0.01% 1900
2014
Q3 		$5.69M Buy
58,700
+25,700
+78% +$2.5M 0.01% 1483
2014
Q2 		$3.03M Sell
33,000
-47,100
-59% -$3.59M ﹤0.01% 1982
2014
Q1 		$5.61M Buy
80,100
+10,100
+14% +$687K 0.01% 1496
2013
Q4 		$4.02M Buy
70,000
+30,000
+75% +$1.58M 0.01% 1882
2013
Q3 		$1.92M Buy
40,000
+20,000
+100% +$729K ﹤0.01% 2465
2013
Q2 		$580K Buy
+20,000
New +$579K ﹤0.01% 3131

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

David Shaw's PCRX Position: Q2 2026 in Review

David Shaw reduced its Pacira BioSciences (PCRX) stake by 1.6% in Q2 2026, selling an estimated $766K and leaving 1,950,332 shares worth $49.5M. The position accounts for 0.02% of the portfolio, ranked #766.

David Shaw first reported a position in PCRX in Q2 2013 and has held it in 41 quarters since. The position peaked at $56.3M in Q1 2025. 251 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

  • David Shaw held 1,950,332 shares of Pacira BioSciences worth $49.5M as of Q2 2026.
  • David Shaw sold 32,392 Pacira BioSciences shares in Q2 2026, an estimated $766K.
  • Pacira BioSciences made up 0.02% of David Shaw's portfolio in Q2 2026, its #766 holding.
  • David Shaw first reported a position in Pacira BioSciences in Q2 2013 and has held it in 41 quarters since.
  • David Shaw's Pacira BioSciences position peaked at $56.3M in Q1 2025.
  • 251 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.